Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Lung Neoplasms 3Neoplasms 2Motor Activity 2Breast Neoplasms 2Anxiety Disorders 2Stress Disorders, Post-Traumatic 1Social Stigma 1Noonan Syndrome 1Neurofibromatosis 1 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Legius syndrome 1Hematologic Neoplasms 1Genetic Diseases, Inborn 1Generalized Anxiety Disorder 1Fatigue 1Depression 1Costello Syndrome 1Chronic Pain 1Cardiofaciocutaneous syndrome 1Breast Cancer With Chronic Lymphedema 1Breast Cancer Female 1

Interventions

pembrolizumab 156Gemcitabine 140Capecitabine 123Paclitaxel 120Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Leucovorin 97Docetaxel 97Cisplatin 89Radiosurgery 88Irinotecan 87Carboplatin 85Cetuximab 72Cyclophosphamide 71Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Waiting Lists × Clear all
NCT03927885 2026-02-19

Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
100 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡